Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
Current Signal: SELL (auto-tracking)
0.86% $1.170
America/New_York / 19 apr 2024 @ 10:53
FUNDAMENTALS | |
---|---|
MarketCap: | 1.715 mill |
EPS: | -33.60 |
P/E: | -0.0300 |
Earnings Date: | Mar 29, 2024 |
SharesOutstanding: | 1.466 mill |
Avg Daily Volume: | 0.121 mill |
RATING 2024-04-18 |
---|
B- |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Neutral | |
P/E: | Neutral | |
Price To Book: | Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.0300 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
0.00x |
Company: PE -0.0300 | industry: PE 222.16 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 1.026 - 1.314 ( +/- 12.31%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-12 | Bambach Kimberly Ann | Buy | 7 500 | Common Stock |
2024-03-12 | Gurfein Blake | Buy | 10 000 | Employee Stock Option (Right to Buy) |
2024-03-12 | Ernst Jennifer | Buy | 32 000 | Employee Stock Option (Right to Buy) |
2023-06-14 | Drexler Karen | Buy | 25 000 | Employee Stock Option (Right to Buy) |
2023-06-14 | Zikria Dean | Buy | 25 000 | Employee Stock Option (Right to Buy) |
INSIDER POWER |
---|
100.00 |
Last 43 transactions |
Buy: 1 440 137 | Sell: 171 652 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $1.170 (0.86% ) |
Volume | 0.0094 mill |
Avg. Vol. | 0.121 mill |
% of Avg. Vol | 7.82 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:25 | sell | $1.200 | N/A | Active |
---|
Tivic Health Systems Inc. operates as a bioelectronic device company that delivers non-invasive neuromodulation products for the treatment of inflammatory conditions. Its primary product is ClearUP, is a medical device intended to relieve sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, including BestBuy.com and FSAStore.com. Tivic Health Systems, Inc. was incorporated in 2016 and is headquartered in Hayward, California.